Dexmedetomidine

Dexmedetomidine (CAS No.: 113775-47-6) is an imidazole small molecule and a highly selective agonist of α₂-adrenergic receptors. It is a classic sedative, analgesic, and sympatholytic drug; it can also directly inhibit TLR4 and multiple voltage-gated ion channels (INa, L-type ICa, delayed-rectifier IK(DR)), and its inhibition of ion channels is independent of α₂ receptors, imidazoline receptors, or α₁ receptors. Its core pathways include: affecting cardiac electrophysiology by inhibiting INa/ICa, reducing the spontaneous beating frequency of hiPSC-CMs, prolonging APD90, and exerting antiarrhythmic effects; downregulating NF-κB activation and proinflammatory factor release by blocking the TLR4-MyD88-NF-κB axis, inhibiting microglial activation, and producing anti-inflammatory and neuroprotective effects; reducing neuronal excitability by inhibiting neuronal IK(DR) and INa, thereby regulating neuronal electrical activity.

At the cellular level, in hiPSC-CMs, the IC50 of dexmedetomidine for inhibiting spontaneous action potential frequency is 27.9 μM, and approximately 30 μM is commonly used for studies of cardiac electrophysiology and antiarrhythmic mechanisms; in HEK-TLR4 reporter cells, the IC50 for inhibiting lipopolysaccharide-induced TLR4 activation is 5.8 μg/mL, and concentration gradients of 0.1–10 μg/mL are often used experimentally to evaluate TLR4 inhibitory effects; in differentiated NG108-15 neuronal cells, the IC50 for inhibiting IK(DR) is 4.6 mM, and concentration ranges of 0.1–30 mM are commonly used in NG108-15 neuronal cells and primary rat cerebellar granule cells to study regulation of sodium, calcium, and potassium channels; BV2 microglial cells are used to verify its anti-inflammatory and neuroprotective effects in attenuating microglial activation and inflammatory factor release through inhibition of the TLR4-NF-κB pathway.

In animal experiments, it is often used for interventional validation in disease models. For example, in a ketamine-induced neuroinjury model in postnatal day 7 SD rat pups, dexmedetomidine is administered intraperitoneally at 50 μg/kg/dose, once every 90 minutes for 6 hours, which can significantly alleviate ketamine-induced microglial activation and related neuroinjury, reflecting its anti-inflammatory and neuroprotective effects.

In clinical applications, dexmedetomidine is a routine medication for intensive care sedation and perioperative sedation and analgesia. It can reduce sympathetic activity while providing sedation and analgesia, thereby reducing the risk of cardiovascular events such as arrhythmias, but its currently approved indications are mainly based on α₂-adrenergic receptor-mediated central effects.

References:

[1] Chen BS, Peng H, Wu SN. Dexmedetomidine, an alpha2-adrenergic agonist, inhibits neuronal delayed-rectifier potassium current and sodium current. Br J Anaesth. 2009 Aug;103(2):244-54. doi: 10.1093/bja/aep107. Epub 2009 Jun 20. PMID: 19542547.

[2] Yang L, Gong Y, Tan Y, Wu L, Witman N, Zheng J, Zhang J, Fu W, Wang W. Dexmedetomidine exhibits antiarrhythmic effects on human-induced pluripotent stem cell-derived cardiomyocytes through a Na/Ca channel-mediated mechanism. Ann Transl Med. 2021 Mar;9(5):399. doi: 10.21037/atm-20-5898. PMID: 33842620; PMCID: PMC8033317.

[3] Koutsogiannaki S, Limratana P, Bu W, Maisat W, McKinstry-Wu A, Han X, Ohto U, Eckenhoff RG, Soriano SG, Yuki K. Dexmedetomidine directly binds to and inhibits Toll-like receptor 4. Int Immunopharmacol. 2024 Nov 15;141:112975. doi: 10.1016/j.intimp.2024.112975. Epub 2024 Aug 19. PMID: 39163686; PMCID: PMC11408083.